DeepMed Research

KATHY MILLER

🇦🇺Australia

Country: 🇦🇺Australia

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

SOC Chemotherapy +/- Tocilizumab for Triple Negative and ER-low Breast Cancers

Phase 2

Recruiting

Conditions: Estrogen-receptor-low Breast Cancer
Metastatic Breast Cancer
Triple Negative Breast Cancer

Interventions: Drug: SOC Chemotherapy
Drug: Tocilizumab

First Posted Date: 2023-05-06

Last Posted Date: 2025-03-18

Lead Sponsor: Kathy Miller

Target Recruit Count: 168

Registration Number: NCT05846789

Locations: 🇺🇸
IU Health Joe and Shelly Schwarz Cancer Center, Carmel, Indiana, United States
🇺🇸
Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana, United States
🇺🇸
Sidney and Lois Eskenazi Hospital, Indianapolis, Indiana, United States

and more 1 locations

Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer

Phase 1

Completed

Conditions: Metastatic Breast Cancer
Hormone Receptor Positive Tumor
Triple Negative Breast Cancer

Interventions: Drug: Talazoparib
Drug: ASTX727

First Posted Date: 2019-10-22

Last Posted Date: 2024-03-22

Lead Sponsor: Kathy Miller

Target Recruit Count: 34

Registration Number: NCT04134884

Locations: 🇺🇸
Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States
🇺🇸
Indiana University Melvin & Bren Simon Cancer Center, Indianapolis, Indiana, United States

An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer

Phase 1

Completed

Conditions: Triple Negative Breast Cancer
Metastatic Breast Cancer

Interventions: Drug: Gedatolisib
Drug: PTK7-ADC

First Posted Date: 2017-08-09

Last Posted Date: 2021-01-07

Lead Sponsor: Kathy Miller

Target Recruit Count: 18

Registration Number: NCT03243331

Locations: 🇺🇸
IU Simon Cancer Center, Indianapolis, Indiana, United States

Inhibiting Fatty Acid Synthase to Improve Efficacy of Neoadjuvant Chemotherapy

Phase 2

Completed

Conditions: Cancer of the Breast

Interventions: Drug: Omeprazole

First Posted Date: 2015-11-03

Last Posted Date: 2021-12-15

Lead Sponsor: Kathy Miller

Target Recruit Count: 42

Registration Number: NCT02595372

Locations: 🇺🇸
Indiana University Health North Hospital, Carmel, Indiana, United States
🇺🇸
Indiana University Health Hospital, Indianapolis, Indiana, United States
🇺🇸
Indiana University Health Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States

and more 6 locations

MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma

Phase 1

Terminated

Conditions: Hepatocellular Carcinoma
Liver Cancer
HCC

Interventions: Drug: MLN0128
Drug: MLN0128 (RP2D)
Drug: Sorafenib

First Posted Date: 2015-10-14

Last Posted Date: 2022-07-26

Lead Sponsor: Kathy Miller

Target Recruit Count: 11

Registration Number: NCT02575339

Locations: 🇺🇸
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸
Penn State Cancer Institute, Hershey, Pennsylvania, United States
🇺🇸
University of Illinois Cancer Center, Chicago, Illinois, United States

and more 3 locations

Impact of LOFT Therapy™ on Breast Cancer Survivors

Not Applicable

Completed

Conditions: Breast Neoplasms

Interventions: Other: LOFT Therapy

First Posted Date: 2015-07-08

Last Posted Date: 2018-08-13

Lead Sponsor: Kathy Miller

Target Recruit Count: 15

Registration Number: NCT02491957

Locations: 🇺🇸
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸
Indiana University Health Hospital, Indianapolis, Indiana, United States

Study Evaluating the Biologic Activity of Guanabenz in Bone Metastasis

Not Applicable

Terminated

Conditions: Bone Cancer
Metastasis

Interventions: Drug: Guanabenz acetate

First Posted Date: 2015-05-13

Last Posted Date: 2018-02-13

Lead Sponsor: Kathy Miller

Target Recruit Count: 4

Registration Number: NCT02443103

Locations: 🇺🇸
Sidney & Lois Eskenazi Hospital, Indianapolis, Indiana, United States
🇺🇸
Indiana University Health Hospital, Indianapolis, Indiana, United States
🇺🇸
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States

and more 1 locations

A Study of Vascular Endothelial Growth Factor (VEGF) Inhibition in Patients With Unilateral Upper Extremity Lymphedema Following Treatment for Cancer

Phase 2

Completed

Conditions: Lymphedema

Interventions: Drug: Pazopanib

First Posted Date: 2009-01-22

Last Posted Date: 2023-10-16

Lead Sponsor: Kathy Miller

Target Recruit Count: 10

Registration Number: NCT00827372

Locations: 🇺🇸
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States

Prev
1
Next

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy